Cutaneous Lupus on Hands: Diagnosis and Treatment

Introduction to Cutaneous Lupus

The American College of Rheumatology recommends prompt evaluation by an experienced dermatologist and often a skin biopsy for accurate diagnosis and appropriate treatment selection of cutaneous lupus on hands 1, 2
Cutaneous lupus on hands may present with photosensitive erythema on dorsal hands, and is often associated with systemic disease activity 2, 4
The European League Against Rheumatism suggests that subacute cutaneous lupus erythematosus (SCLE) is associated with anti-Ro/SSA antibodies 3

Diagnosis requires evaluation by an experienced dermatologist and often a skin biopsy for histological analysis 1, 2
The Cutaneous Lupus Disease Area and Severity Index (CLASI) may be used to assess disease activity and damage 1, 5
Laboratory tests including anti-dsDNA, anti-Ro/SSA, anti-La/SSB, and complement levels may help determine systemic involvement 2, 4

The American Academy of Dermatology recommends photoprotection as crucial for all cutaneous lupus patients with hand involvement 6, 7
Topical corticosteroids or calcineurin inhibitors may be used for mild to moderate disease 3, 6
Hydroxychloroquine is effective for all types of cutaneous lupus and may be used as monotherapy or in combination with other agents 6
Systemic corticosteroids may be used for acute flares or severe disease, but should be minimized to less than 7.5 mg/day for chronic use 3, 6
Immunosuppressive agents such as methotrexate or mycophenolate mofetil may be used for non-responsive cases 6, 8
Biologics such as belimumab or rituximab may be considered for refractory disease 6, 8

Manual lymph drainage may improve hand function in patients with puffy hands 10
Physical exercise should be considered to maintain hand function and reduce stiffness 7, 10
Management of Raynaud's phenomenon includes use of gloves and heating devices, avoidance of cold exposure, and may require vasodilators in severe cases 8, 11

Regular assessment of disease activity using validated tools like CLASI is recommended 1, 5
Monitoring for medication side effects, such as ophthalmologic screening for antimalarials, is necessary 6
Evaluation for development of systemic disease is also recommended 2, 4